Squarepoint
OMED

Squarepoint’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Squarepoint’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-54,091
Closed -$222K – 2501
2017
Q4 		$222K Buy
54,091
+31,191
+136% +$136K ﹤0.01% 1741
2017
Q3 		$104K Buy
22,900
+3,649
+19% +$14.8K ﹤0.01% 1507
2017
Q2 		$64K Buy
+19,251
New +$79.9K ﹤0.01% 1441

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Squarepoint's OMED Position: Q1 2018 in Review

Squarepoint sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 54,091 shares — an estimated $222K sold.

Squarepoint first reported a position in OMED in Q2 2017 and held it in 3 quarters. The position peaked at $222K in Q4 2017. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

  • Squarepoint reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Squarepoint sold 54,091 OncoMed Pharmaceuticals, Inc. shares in Q1 2018, an estimated $222K.
  • Squarepoint first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
  • Squarepoint's OncoMed Pharmaceuticals, Inc. position peaked at $222K in Q4 2017.
  • 66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on Squarepoint's 13F filing for Q1 2018, filed 15 May 2018.